BackCyclo Therapeutics- Warrants (14/11/2025) Overview

Cyclo Therapeutics- Warrants (14/11/2025) Current Cash

Latest current cash for CYTHW: $930K.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$928010.00
48.50% YoYΔ $-873799.00 vs prior year quarter

Peer average

Loading

Cyclo Therapeutics- Warrants (14/11/2025) Current Cash History

Loading

Cyclo Therapeutics- Warrants (14/11/2025) vs. peers: Current Cash Comparison

Loading

Cyclo Therapeutics- Warrants (14/11/2025) Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Cyclo Therapeutics- Warrants (14/11/2025) (CYTHW) FAQ

As of the most recent data (September 2024), CYTHW shows a current cash of $930K. That compares with $1.8M in the prior-year period — down 48.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CYTHW's current cash is now $930K (was $1.8M) — a 48.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Cyclo Therapeutics- Warrants (14/11/2025) is outperforming or lagging.

Tracking CYTHW's current cash over time shows whether Cyclo Therapeutics- Warrants (14/11/2025) is scaling, shrinking, or reshaping that part of the business. The current reading is $930K That compares with $1.8M in the prior-year period — down 48.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Cyclo Therapeutics- Warrants (14/11/2025)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $930K) with ownership activity and broader fundamentals.

Cyclo Therapeutics- Warrants (14/11/2025)'s current cash is $930K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.